Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide

被引：58
|
作者：
Singh, Naveena [1 ]
Gilks, C. Blake [2 ]
Hirschowitz, Lynn [3 ]
Kehoe, Sean [4 ]
McNeish, Iain A. [5 ]
Miller, Dianne [6 ,7 ]
Naik, Raj [8 ]
Wilkinson, Nafisa [9 ]
McCluggage, W. Glenn [10 ]
机构：
[1] Barts Hlth NHS Trust, Dept Cellular Pathol, 80 Newark St, London E11 1LT, England
[2] Vancouver Gen Hosp, Dept Anat Pathol, 1st Floor JPPN,855 West 12th Ave, Vancouver, BC V5Z 1M9, Canada
[3] Birmingham Womens NHS Trust, Dept Cellular Pathol, Mindelsohn Way, Birmingham B15 2TG, W Midlands, England
[4] Univ Birmingham, Inst Canc & Genom, Birmingham B15 2TT, W Midlands, England
[5] Univ Glasgow, Wolfson Wohl Canc Res Ctr, Inst Canc Sci, Beatson Inst Canc Res, Glasgow G61 1QH, Lanark, Scotland
[6] Vancouver Gen Hosp, Div Gynecol Oncol, 6th Floor Gynecol,2775 Laurel St, Vancouver, BC V5Z 1M9, Canada
[7] British Columbia Canc Agcy, Gordon & Leslie Diamond Hlth Care Ctr, 6th Floor Gynecol,2775 Laurel St, Vancouver, BC V5Z 1M9, Canada
[8] Queen Elizabeth Hosp, Dept Gynaecol Oncol, Queen Elizabeth Ave, Gateshead NE9 6SX, Tyne & Wear, England
[9] St James Hosp, Dept Pathol, Beckett St, Leeds LS9 7TF, W Yorkshire, England
[10] Royal Victoria Hosp, Dept Pathol Belfast Hlth & Social Care Trust, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland
来源：
GYNECOLOGIC ONCOLOGY | 2016年 / 141卷 / 02期
关键词：
Ovary; High-grade serous carcinoma; Fallopian tube; Primary peritoneal carcinoma; Pathology; Origin; FALLOPIAN-TUBE; INTRAEPITHELIAL CARCINOMA; FIMBRIA; OVARY; ORIGIN; SYSTEM; BRCA;
D O I：
10.1016/j.ygyno.2015.10.022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195 / 198
页数：4
相关论文
共 50 条
  • [31] Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival
    Zwimpfer, T. A.
    Pandey, A.
    Fereday, S.
    Coelho, R. J. B-N.
    Twomey, L.
    Ariyaratne, D.
    Traficante, N.
    Jacob, F.
    Eller, R.
    Heinzelmann-Schwarz, V.
    Christie, E. L.
    Kennedy, C.
    Au-Yeung, G.
    Ramus, S.
    Koebel, M.
    Nelson, B.
    Goode, E. L.
    DeFazio, A.
    Bowtell, D. D. L.
    Garsed, D. W.
    ANNALS OF ONCOLOGY, 2024, 35 : S571 - S571
  • [32] Quantifying intratumoral biomarker heterogeneity in tubo-ovarian high-grade serous carcinoma to optimize clinical translation
    Talhouk, Aline
    Chiu, Derek S.
    Meunier, Liliane
    Rahimi, Kurosh
    Le Page, Cecile
    Bernard, Monique
    Provencher, Diane
    Huntsman, David G.
    Masson, Anne Marie Mes
    Kobel, Martin
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [33] The secondary Mullerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters
    Singh, Naveena
    Gilks, C. Blake
    Wilkinson, Nafisa
    McCluggage, W. Glenn
    PATHOLOGY, 2015, 47 (05) : 423 - 431
  • [34] Personalization of Therapy in High-Grade Serous Tubo-Ovarian Cancer-The Possibility or the Necessity?
    Wilczynski, Jacek
    Paradowska, Edyta
    Wilczynski, Milosz
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (01):
  • [35] A Proteogenomic Analysis of Transitional Cell Carcinoma, the TCC-Like Variant of Tubo-Ovarian High-Grade Serous Carcinoma
    Tessier-Cloutier, Basile
    Cochrane, Dawn
    Karnezis, Anthony
    Colborne, Shane
    Magrill, Jamie
    Talhouk, Aline
    Zhang, Jonathan
    Soslow, Robert
    Morin, Gregg
    Hughes, Christopher
    Piskorz, Anna
    Cheng, Angela
    Greening, Kendall
    Prader, Sonja
    Pfisterer, Jacobus
    Gilks, C. Blake
    Kommoss, Stefan
    Brenton, James
    Huntsman, David
    Kommoss, Friedrich
    LABORATORY INVESTIGATION, 2019, 99
  • [36] PrOTYPE (Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE): The development and validation of a clinical-grade consensus classifier for the molecular subtypes of high-grade serous tubo-ovarian cancer.
    Talhouk, Aline
    George, Joshy
    Wang, Chen
    Goode, Ellen
    Ramus, Susan
    Doherty, Jennifer
    Bowtell, David
    Anglesio, Michael
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 38 - 38
  • [37] Tubo-ovarian high-grade serous carcinomas commonly express CA19.9
    Rajendran, Simon
    McCluggage, W. Glenn
    HISTOPATHOLOGY, 2022, 80 (02) : 449 - 450
  • [38] A Proteogenomic Analysis of Transitional Cell Carcinoma, the TCC-Like Variant of Tubo-Ovarian High-Grade Serous Carcinoma
    Tessier-Cloutier, Basile
    Cochrane, Dawn
    Karnezis, Anthony
    Colborne, Shane
    Magrill, Jamie
    Talhouk, Aline
    Zhang, Jonathan
    Soslow, Robert
    Morin, Gregg
    Hughes, Christopher
    Piskorz, Anna
    Cheng, Angela
    Greening, Kendall
    Prader, Sonja
    Pfisterer, Jacobus
    Gilks, C. Blake
    Kommoss, Stefan
    Brenton, James
    Huntsman, David
    Kommoss, Friedrich
    MODERN PATHOLOGY, 2019, 32
  • [39] HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma
    Koskela, Heidi
    Li, Yilin
    Joutsiniemi, Titta
    Muranen, Taru
    Isoviita, Veli-Matti
    Huhtinen, Kaisa
    Micoli, Giulia
    Lavikka, Kari
    Marchi, Giovanni
    Hietanen, Sakari
    Virtanen, Anni
    Hautaniemi, Sampsa
    Oikkonen, Jaana
    Hynninen, Johanna
    GYNECOLOGIC ONCOLOGY, 2024, 180 : 91 - 98
  • [40] Neoadjuvant Chemotherapy for Tubo-ovarian High-grade Serous Carcinoma: Correlation of Clinical Response with Tumor Morphology and Immunophenotype
    Liu, Yuxin
    Schwartz, Melissa
    Kalir, Tamara
    MODERN PATHOLOGY, 2018, 31 : 436 - 436
12345